Drugs / Fipamezole
Fipamezole
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00040209 | Jun 2002 → Jul 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00758849 Comparator | Sep 2008 → May 2009 | Parkinson disease, multiple system atrophy, orthostatic hypotension | Juvantia Pharma Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT00559871 Comparator | Oct 2007 → May 2009 | Parkinson disease | Juvantia Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fipamezole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00559871 ↗ |
| Known as | Fipamezol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1255582 ↗ |
| Known as | JP-1730 | “This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms” NCT00040209 ↗ |
| Action | Inhibit | “selective alpha-2 adrenergic receptor antagonism” NCT00040209 ↗ |
| Modality | Small molecule | — CHEMBL1255582 ↗ |
| Route | Oral | “via puffs from an oral spray” NCT00040209 ↗ |